Kenneth Myszkowski's most recent trade in Arrowhead Pharmaceuticals Inc. was a trade of 100,000 Common Stock done . Disclosure was reported to the exchange on Jan. 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2025 | 100,000 | 500,600 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.68 per share. | 04 Jan 2025 | 17,765 | 482,835 (0%) | 0% | 19.7 | 349,615 | Common Stock |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 04 Jan 2025 | 10,000 | 455,433 (0%) | 0% | 19.7 | 196,900 | Common Stock |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.10 per share. | 04 Jan 2025 | 9,402 | 473,433 (0%) | 0% | 20.1 | 188,980 | Common Stock |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.70 per share. | 04 Jan 2025 | 8,000 | 465,433 (0%) | 0% | 19.7 | 157,600 | Common Stock |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 06 Mar 2024 | 40,000 | 400,600 (0%) | 0% | 35.2 | 1,407,600 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 04 Jan 2024 | 75,000 | 456,704 (0%) | 0% | 0 | Common Stock | ||
| Arrowhead Pharma Inc | Myszkowski Kenneth | Chief Financial Officer | 04 Jan 2024 | 8,904 | 440,600 (0%) | 0% | 35.7 | 317,428 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 04 Jan 2024 | 5,800 | 449,504 (0%) | 0% | 35.0 | 202,826 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 04 Jan 2024 | 1,400 | 455,304 (0%) | 0% | 34.0 | 47,656 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 27 Jun 2023 | 15,000 | 381,704 (0%) | 0% | 36.2 | 543,000 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 04 Jan 2023 | 60,000 | 396,704 (0%) | 0% | 0 | Common Stock | ||
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 30 Sep 2022 | 96,676 | 367,329 (0%) | 0% | 0 | Common Stock | ||
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 05 Jan 2022 | 16,528 | 471,569 (0%) | 0% | 62 | 1,024,736 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 05 Jan 2022 | 15,908 | 488,097 (0%) | 0% | 60.5 | 962,434 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 05 Jan 2022 | 3,786 | 464,005 (0%) | 0% | 64.0 | 242,115 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 05 Jan 2022 | 3,778 | 467,791 (0%) | 0% | 63.2 | 238,656 | Common Stock | |
| Arrowhead Pharma Inc | Kenneth Myszkowski | Chief Financial Officer | 01 Jan 2022 | 60,000 | 504,005 (0%) | 0% | 0 | Common Stock |